---
layout: default
title: Temozolomide
description: "Temozolomide çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æœ€é«˜è­‰æ“šç­‰ç´š L1ï¼ŒåŒ…å« 2 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 163
evidence_level: L1
indication_count: 2
---

# Temozolomide

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L1</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>2</strong> å€‹ | å»ºè­°æ±ºç­–: <strong style="color: #2E7D32;">Go</strong>
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Temozolomide å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
<strong>Temozolomide</strong> æ˜¯ä¸€ç¨®å£æœçƒ·åŒ–åŠ‘ï¼ŒåŸæœ¬ç”¨æ–¼æ²»ç™‚æ–°è¨ºæ–·åŠå¾©ç™¼çš„æƒ¡æ€§ç¥ç¶“è† è³ªç˜¤ï¼ˆå¦‚ç¥ç¶“è† æ¯ç´°èƒç˜¤ï¼‰ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°<strong>æˆäººæ˜Ÿç‹€ç´°èƒç˜¤ (Adult Astrocytic Tumour)</strong> æœ‰æ•ˆï¼Œç›®å‰æœ‰ <strong>2 å€‹è‡¨åºŠè©¦é©—</strong>å’Œ<strong>è¶…é 20 ç¯‡æ–‡ç»</strong>æ”¯æŒé€™å€‹æ–¹å‘ï¼Œå±¬æ–¼æœ€é«˜è­‰æ“šç­‰ç´š L1ã€‚
</p>

<div class="key-takeaway">
Temozolomide ç”¨æ–¼æˆäººæ˜Ÿç‹€ç´°èƒç˜¤çš„è­‰æ“šå……åˆ†ï¼Œå°ç£ç¾æœ‰é©æ‡‰ç—‡å·²æ¶µè“‹é€€è¡Œæ€§æ˜Ÿç‹€ç´°èƒç˜¤ï¼ŒTxGNN é æ¸¬èˆ‡è‡¨åºŠå¯¦å‹™é«˜åº¦å»åˆã€‚
</div>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | ç¥ç¶“è† æ¯ç´°èƒç˜¤ï¼ˆèˆ‡æ”¾å°„æ²»ç™‚åŒæ­¥åŠè¼”åŠ©æ²»ç™‚ï¼‰ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | adult astrocytic tumourã€cauda equina neoplasm |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.36% |
| è­‰æ“šç­‰ç´š | L1 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Go |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. adult astrocytic tumour</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.36%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

<p class="key-answer" data-question="Temozolomide çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ">
Temozolomide æ˜¯ä¸€ç¨®å’ªå”‘å¹¶å››å—ªé¡çƒ·åŒ–åŠ‘ï¼Œé€é DNA ç”²åŸºåŒ–ä½œç”¨æŠ‘åˆ¶è…«ç˜¤ç´°èƒçš„ DNA è¤‡è£½ã€‚å®ƒåœ¨ç”Ÿç†æ¢ä»¶ä¸‹è‡ªç™¼è½‰åŒ–ç‚ºæ´»æ€§ä»£è¬ç‰© MTICï¼Œèƒ½ç©¿é€è¡€è…¦å±éšœï¼Œå°ä¸­æ¨ç¥ç¶“ç³»çµ±è…«ç˜¤å…·æœ‰è‰¯å¥½çš„ç™‚æ•ˆã€‚
</p>

<blockquote class="expert-quote">
ã€Œç¥ç¶“è† æ¯ç´°èƒç˜¤ï¼ˆWHO ç¬¬ 4 ç´šï¼‰å’Œé€€è¡Œæ€§æ˜Ÿç‹€ç´°èƒç˜¤ï¼ˆWHO ç¬¬ 3 ç´šï¼‰åŒå±¬æ˜Ÿç‹€ç´°èƒä¾†æºçš„ç¥ç¶“è† è³ªç˜¤ï¼Œåœ¨ç—…ç†å­¸å’Œåˆ†å­ç‰¹å¾µä¸Šæœ‰é«˜åº¦é‡ç–Šã€‚ã€
<cite>â€” åŸºæ–¼ WHO CNS è…«ç˜¤åˆ†é¡</cite>
</blockquote>

äº‹å¯¦ä¸Šï¼ŒTemozolomide çš„å°ç£æ ¸å‡†é©æ‡‰ç—‡å·²åŒ…å«ã€Œçµ¦äºˆæ¨™æº–æ²»ç™‚å¾Œå¾©ç™¼æ€§æˆ–æƒ¡åŒ–ä¹‹æƒ¡æ€§ç¥ç¶“è† è³ªç˜¤ï¼Œä¾‹å¦‚å¤šå½¢ç¥ç¶“è† æ¯ç´°èƒç˜¤æˆ–é€€è¡Œæ€§æ˜Ÿç‹€ç´°èƒç˜¤ã€ï¼Œé¡¯ç¤ºé€™å€‹é æ¸¬èˆ‡ç¾æœ‰é©æ‡‰ç—‡é«˜åº¦ä¸€è‡´ã€‚

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| [NCT00960492](https://clinicaltrials.gov/study/NCT00960492) | Phase 1 | å®Œæˆ | 26 | è©•ä¼° XL184 åˆä½µ Temozolomide å’Œæ”¾å°„æ²»ç™‚ç”¨æ–¼ç¬¬ 4 ç´šæ˜Ÿç‹€ç´°èƒè…«ç˜¤çš„å®‰å…¨æ€§å’Œè—¥ç‰©å‹•åŠ›å­¸ |
| [NCT00052455](https://clinicaltrials.gov/study/NCT00052455) | Phase 3 | å®Œæˆ | 500 | æ¯”è¼ƒ Temozolomide å–®è—¥èˆ‡ PCV åŒ–ç™‚æ–¹æ¡ˆç”¨æ–¼å¾©ç™¼æ€§ WHO ç¬¬ 3-4 ç´šæ˜Ÿç‹€ç´°èƒç˜¤ï¼Œä¸»è¦çµ‚é»ç‚ºç¸½å­˜æ´»æœŸ |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [15758009](https://pubmed.ncbi.nlm.nih.gov/15758009/) | 2005 | Phase 3 RCT | NEJM | é‡Œç¨‹ç¢‘ç ”ç©¶ï¼šæ”¾å°„æ²»ç™‚åˆä½µ Temozolomide é¡¯è‘—å»¶é•·ç¥ç¶“è† æ¯ç´°èƒç˜¤æ‚£è€…å­˜æ´» |
| [26670971](https://pubmed.ncbi.nlm.nih.gov/26670971/) | 2015 | Phase 3 RCT | JAMA | è…«ç˜¤é›»å ´æ²»ç™‚åˆä½µ Temozolomide ç¶­æŒæ²»ç™‚å„ªæ–¼å–®ç¨ Temozolomide |
| [30782343](https://pubmed.ncbi.nlm.nih.gov/30782343/) | 2019 | Phase 3 RCT | Lancet | Lomustine-Temozolomide åˆä½µæ²»ç™‚åœ¨ MGMT å•Ÿå‹•å­ç”²åŸºåŒ–çš„æ–°è¨ºæ–·ç¥ç¶“è† æ¯ç´°èƒç˜¤ä¸­å„ªæ–¼æ¨™æº– Temozolomide |
| [22578793](https://pubmed.ncbi.nlm.nih.gov/22578793/) | 2012 | Phase 3 RCT | Lancet Oncol | è€å¹´æƒ¡æ€§æ˜Ÿç‹€ç´°èƒç˜¤æ‚£è€…å–®ç¨ä½¿ç”¨ Temozolomide vs æ”¾å°„æ²»ç™‚çš„æ¯”è¼ƒ |
| [25920709](https://pubmed.ncbi.nlm.nih.gov/25920709/) | 2015 | Phase 2 RCT | J Neurooncol | æ”¾å°„æ²»ç™‚åˆä½µ Temozolomide ç”¨æ–¼é€€è¡Œæ€§æ˜Ÿç‹€ç´°èƒè† è³ªç˜¤ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. cauda equina neoplasm</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.30%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.30%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›ç½²è—¥è¼¸å­— | å¸ç›Ÿå¤šè† å›Š | è† å›ŠåŠ‘ | æ–°è¨ºæ–·çš„å¤šå½¢ç¥ç¶“è† æ¯ç´°èƒç˜¤ï¼Œèˆ‡æ”¾å°„æ²»ç™‚åŒæ­¥é€²è¡Œ... |
| è¡›éƒ¨èŒç–«è¼¸å­—ç¬¬001117è™Ÿ | è‰¾æ³•æ–½æ³¨å°„æ¶² | æ³¨å°„æ¶²åŠ‘ | æƒ¡æ€§ç¥ç¶“è† è³ªç˜¤ï¼ˆèˆ‡å« Temozolomide åŒ–ç™‚å¤±æ•—å¾Œä½¿ç”¨ï¼‰ |

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | å‚³çµ±ç´°èƒæ¯’æ€§è—¥ç‰©ï¼ˆçƒ·åŒ–åŠ‘ï¼‰ |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | ä¸­åº¦ï¼ˆå¸¸è¦‹è¡€å°æ¿æ¸›å°‘ã€å—œä¸­æ€§ç™½è¡€çƒæ¸›å°‘ï¼‰ |
| è‡´åæ€§åˆ†ç´š | ä¸­åº¦ |
| ç›£æ¸¬é …ç›® | CBCï¼ˆå«åˆ†é¡ï¼‰ã€è‚åŠŸèƒ½ã€éœ€åœ¨é–‹å§‹æ²»ç™‚å‰åŠæ•´å€‹æ²»ç™‚æœŸé–“ç›£æ¸¬è¡€æ¶²å­¸åƒæ•¸ |
| è™•ç½®é˜²è­· | éœ€ä¾ç´°èƒæ¯’æ€§è—¥ç‰©è™•ç½®è¦ç¯„æ“ä½œ |

## å®‰å…¨æ€§è€ƒé‡

å®‰å…¨æ€§è³‡è¨Šè«‹åƒè€ƒåŸå» ä»¿å–®ã€‚ä¸»è¦æ³¨æ„äº‹é …åŒ…æ‹¬ï¼š
- éª¨é«“æŠ‘åˆ¶ï¼šéœ€å®šæœŸç›£æ¸¬è¡€çƒè¨ˆæ•¸
- è‚æ¯’æ€§ï¼šéœ€ç›£æ¸¬è‚åŠŸèƒ½
- è‡´ç•¸æ€§ï¼šå­•å©¦ç¦ç”¨


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Hepatic Insufficiency** ğŸŸ¡ Moderate
- A study showed that the pharmacokinetics of temozolomide in patients with mild-to-moderate hepatic impairment (Child-Pugh Class I - II) were similar to those observed in patients with normal hepatic function.  Caution should be exercised when temozol...

**Bone Marrow Failure Disorders** ğŸŸ¡ Moderate
- Patients treated with temozolomide may experience myelosuppression, including prolonged pancytopenia, which may result in aplastic anemia, which in some cases has resulted in a fatal outcome.  Prior to dosing, patients must have an absolute neutrophi...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- Temozolomide population pharmacokinetic analysis indicated that creatinine clearance over the range of 36 to 130 mL/min/m2 has no effect on its clearance after oral administration.  The pharmacokinetics of temozolomide have not been studied in patien...

**Urticaria** ğŸŸ¢ Minor
- Temozolomide is contraindicated in patients with a history of urticaria, allergic reaction including anaphylaxis, toxic epidermal necrolysis, and Stevens-Johnson syndrome.

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

<p class="key-answer" data-question="Temozolomide ç”¨æ–¼æˆäººæ˜Ÿç‹€ç´°èƒç˜¤çš„å»ºè­°æ±ºç­–æ˜¯ä»€éº¼ï¼Ÿ">
<strong>æ±ºç­–ï¼šGo</strong> â€” Temozolomide ç”¨æ–¼æˆäººæ˜Ÿç‹€ç´°èƒç˜¤çš„è­‰æ“šå……åˆ†ï¼Œå·²æœ‰å¤šå€‹ Phase 3 RCT æ”¯æŒå…¶ç™‚æ•ˆã€‚å°ç£ç¾æœ‰é©æ‡‰ç—‡å·²æ¶µè“‹é€€è¡Œæ€§æ˜Ÿç‹€ç´°èƒç˜¤ï¼ŒTxGNN é æ¸¬èˆ‡è‡¨åºŠå¯¦å‹™é«˜åº¦å»åˆã€‚
</p>

<ol class="actionable-steps">
<li>ç¢ºèªç‰¹å®šäºå‹æ˜Ÿç‹€ç´°èƒç˜¤çš„ MGMT ç”²åŸºåŒ–ç‹€æ…‹ä»¥é æ¸¬ç™‚æ•ˆ</li>
<li>é‡å°ä¸åŒåˆ†å­äºå‹åˆ¶å®šå€‹äººåŒ–æ²»ç™‚æ–¹æ¡ˆ</li>
<li>åƒè€ƒç¾æœ‰ Phase 3 RCT æ•¸æ“šé€²è¡ŒåŠ‘é‡èˆ‡ç™‚ç¨‹è¦åŠƒ</li>
</ol>


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Naftifine]({{ "/drugs/naftifine/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Ipratropium]({{ "/drugs/ipratropium/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Icatibant]({{ "/drugs/icatibant/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Docetaxel]({{ "/drugs/docetaxel/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Anastrozole]({{ "/drugs/anastrozole/" | relative_url }}) - è­‰æ“šç­‰ç´š L1

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Temozolomideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/temozolomide/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_temozolomide,
  title = {Temozolomideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/temozolomide/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-19 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
